The Treat All policy, then, only extends ART to PLHIV with already normal or lightly compromised CD4+ T-cell counts and are already in a better position to combat Mtb infections, which leads to a marginal or insignificant effect on TB outcomes. Here, CD4 is linked to tuberculosis.